Haleon (HLN) Stock Price, News & Analysis

Company Overview

Haleon plc is a consumer healthcare company that designs, manufactures and markets a broad range of well-known health and wellness products. Established as an independent entity in July 2022 following its spin-off from GSK’s consumer healthcare division, Haleon focuses on categories such as oral health, pain relief, respiratory health, digestive health and vitamins, minerals and supplements. Its portfolio includes globally recognized brands like Sensodyne, Advil, Centrum, Voltaren and Panadol, which are sold through retail pharmacies, supermarkets and e-commerce channels.

With headquarters in Weybridge, England, Haleon serves consumers across more than 100 markets worldwide. The company operates regional hubs in North America, Europe, Latin America, the Middle East and Asia Pacific, adapting its product offerings to local preferences and regulatory standards. Haleon maintains manufacturing sites in key locations and partners with contract manufacturers to ensure robust supply chains and product availability for consumers across diverse geographies.

Haleon emphasizes research and development to support new product innovation, leveraging clinical science and consumer insights to address unmet healthcare needs. Its R&D centers collaborate with academic institutions and external research organizations to develop next-generation formulations and delivery formats. Sustainability and responsible sourcing are also central to Haleon’s strategy, with ongoing efforts to reduce environmental impact and enhance the recyclability of packaging materials.

Under the leadership of Chief Executive Officer Brian McNamara and Chief Financial Officer Colin Baird, Haleon is guided by a commitment to long-term growth and value creation. The company’s board and executive team bring extensive experience from the pharmaceutical, consumer goods and healthcare industries. Their collective expertise supports Haleon’s mission to improve everyday health for people around the world by delivering trusted, scientifically backed products.

Key Stats

• Today's Range: $9.72 to $9.79
• 50-Day Range: $9.28 to $10.36
• 52-Week Range: $8.86 to $11.42
• Volume: 6.16 million shs
• Average Volume: 7.98 million shs
• Market Capitalization: $43.76 billion
• P/E Ratio: 25.05
• Dividend Yield: 1.13%
• Price Target: $12.33
• Consensus Rating: Moderate Buy

Haleon Stock Analysis - MarketRank™

Haleon scored higher than 75% of companies evaluated by MarketBeat, and ranked 257th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Haleon has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Haleon has a consensus price target of $12.33, representing about 26.2% upside from its current price of $9.77.

Amount of Analyst Coverage

Haleon has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 13.95%

Earnings Growth

Earnings for Haleon are expected to grow by 13.95% in the coming year, from $0.43 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Haleon is 25.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 278.42.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haleon is 25.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.75.

Price to Earnings Growth Ratio

Haleon has a PEG Ratio of 2.89. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haleon has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.46% of the float of Haleon has been sold short.

Short Interest Ratio / Days to Cover

Haleon has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Haleon has recently increased by 17.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Haleon pays a meaningful dividend of 1.13%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Haleon does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Haleon is 28.21%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Haleon will have a dividend payout ratio of 22.45% next year. This indicates that Haleon will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.46% of the float of Haleon has been sold short.

Short Interest Ratio / Days to Cover

Haleon has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Haleon has recently increased by 17.65%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.08

News Sentiment

Haleon has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Haleon this week, compared to 7 articles on an average week.

MarketBeat Follows

3 people have added Haleon to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Haleon insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 6.67% of the stock of Haleon is held by institutions.

HLN Stock Analysis - Frequently Asked Questions

How have HLN shares performed this year?

Haleon's stock was trading at $9.54 at the start of the year. Since then, HLN stock has increased by 2.4% and is now trading at $9.77.

How were Haleon's earnings last quarter?

Haleon PLC Sponsored ADR (NYSE:HLN) released its earnings results on Thursday, February, 27th. The company reported $0.05 EPS for the quarter. The firm earned $3.54 billion during the quarter, compared to analyst estimates of $3.38 billion. Haleon had a trailing twelve-month return on equity of 17.65% and a net margin of 12.86%.
Read the conference call transcript.

Who are Haleon's major shareholders?

Haleon's top institutional shareholders include Dodge & Cox (3.46%), Bank of America Corp DE (0.28%), Sculptor Capital LP (0.22%) and JPMorgan Chase & Co. (0.20%).

How do I buy shares of Haleon?

Shares of HLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Haleon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Haleon investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 2/27/2025
• Record date for 9/18 Dividend: 8/15/2025
• Ex-Dividend for 9/18 Dividend: 8/15/2025
• Today: 9/09/2025
• Dividend Payable: 9/18/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Consumer Goods
• Current Symbol: NYSE:HLN
• CIK: 1900304
• Web: www.haleon.com
• Phone: 44-19-3282-2000
• Fax: N/A
• Employees: 24,561
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Haleon: $12.33
• High Price Target: $13.40
• Low Price Target: $11.25
• Potential Upside/Downside: +26.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.39
• Trailing P/E Ratio: 25.00
• Forward P/E Ratio: 22.71
• P/E Growth: 2.89
• Net Income: $1.84 billion
• Net Margins: 12.86%
• Pretax Margin: 17.00%
• Return on Equity: 17.65%
• Return on Assets: 8.58%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 0.87
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: $14.35 billion
• Price / Sales: 3.05
• Cash Flow: $0.50 per share
• Price / Cash Flow: 19.66
• Book Value: $4.58 per share
• Price / Book: 2.13

Miscellaneous

• Outstanding Shares: 4,478,700,000
• Free Float: N/A
• Market Cap: $43.73 billion
• Optionable: Not Optionable
• Beta: 0.23